MERCK DOWNPLAYS TAGAMET EXPERIENCE FOR PEPCID AC OTC SWITCH REVIEW
This article was originally published in The Tan Sheet
Executive Summary
MERCK DOWNPLAYS TAGAMET EXPERIENCE FOR PEPCID AC OTC SWITCH REVIEW during an April 12 meeting with securities analysts at Merck's research facilities in Rahway, N.J. Merck Research Labs President Edward Scolnick, MD, maintained that Merck has "much better data" on its H[2] antagonist Pepcid (famotidine) for the treatment of heartburn than SmithKline Beecham had for Tagamet (cimetidine). "It is a completely different world of clinical research that our group has generated," Scolnick told the analysts.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning